Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
BörsenkürzelCELZ
Name des UnternehmensCreative Medical Technology Holdings Inc
IPO-datumMay 01, 2009
CEOMr. Timothy Warbington
Anzahl der mitarbeiter4
WertpapierartOrdinary Share
GeschäftsjahresendeMay 01
Addresse211 E. Osborn Rd.
StadtPHOENIX
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl85012
Telefon14803992822
Websitehttps://creativemedicaltechnology.com/
BörsenkürzelCELZ
IPO-datumMay 01, 2009
CEOMr. Timothy Warbington
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten